CDC’s Mission on IBD

We work to understand the epidemiology of inflammatory bowel disease (IBD) to effectively target interventions and inform best clinical practices by:

Gathering national prevalence and incidence data.
Supporting population-based studies to describe demographic and clinical characteristics of people with IBD and to assess the impact of the disease and various clinical practices in managing IBD.
Adapting and expanding current studies to capture socio-economic, racial, and geographic differences among the population.

CDC-Funded Projects

Project Aims

Build a registry of patients with incident diagnosis of CD and UC by leveraging the existing infrastructure of two highly successful pediatric and adult research networks.
Estimate the incidence and prevalence of CD and UC at a national level using representative data that encompasses populations from all segments of the socioeconomic and geographic distribution of the United States.
Determine whether race and IBD practice volume are associated with patterns of care and key outcomes including use of biologics, steroids, narcotics, hospitalization, and surgery at a national level and within high volume IBD centers.

Relevant References

Selected Publications.¹

Crohn’s & Colitis Foundationexternal icon

Project Aims

Develop and implement a prototype for a national surveillance system to collect estimates of the incidence and prevalence of IBD in the US.
Determine the impact of IBD on affected persons.
Identify psychosocial, economic, demographic, clinical, and biological variables associated with disparate outcomes in IBD.
Develop programs to address variations in clinical practice that are associated with disparate outcomes in IBD in order to improve disease outcomes.

Relevant References

Selected publications.^2-7

Crohn’s & Colitis Foundationexternal icon

References

More than 2.6 million cases of provider-diagnosed inflammatory bowel disease in the United States. Digestive Disease Week. 2022; abstract, San Diego, CA.
Shapiro JM, Zoega H, Shah SA, Bright RM. Incidence of Crohn’s disease and ulcerative colitis in Rhode Island: report from the Ocean State Crohn’s and Colitis Area Registry. Inflamm Bowel Dis. 2016;22(6):1456‒1461.
Shmidt E, Suárez-Fariñas M, Mallette M et al. Erectile Dysfunction is highly prevalent in men with newly diagnosed inflammatory bowel disease. Inflamm Bowel Dis. 2019;25(8):1408‒1416. doi: 10.1093/ibd/izy401.
Shmidt E, Suárez-Fariñas M, Mallette M et al. A longitudinal study of sexual function in women with newly diagnosed inflammatory bowel disease. Inflamm Bowel Dis. 2019;25(7):1262‒1270. doi: 10.1093/ibd/izy397.
Cohen BL, Zoega H, Shah SA et al. Fatigue is highly associated with poor health-related quality of life, disability and depression in newly-diagnosed patients with inflammatory bowel disease, independent of disease activity. Aliment Pharmacol Ther. 2014;39(8):811‒822. doi: 10.1111/apt.12659.
Shapiro JM, Hagin SE, Shah SA, et al. Corticosteroid use in a prospective, community-based cohort of newly diagnosed inflammatory bowel disease patients. Dig Dis Sci. 2016;61(6):1635‒1640. doi: 10.1007/s10620-015-4010-4.
Shapiro JM, de Zoete MR, Palm NW et al. Immunoglobulin a targets a unique subset of the Microbiota in inflammatory bowel disease. Cell Host Microbe. 2021;29(1):83‒93.e3. doi: 10.1016/j.chom.2020.12.003.

Page last reviewed: April 14, 2022

Content source: National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention